CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications

Rhea-AI Summary

CanaQuest Medical Corp (OTC PINK:CANQF) has appointed Rob Rinderman as its new Director of Communications. Rinderman, with over 35 years of experience in Wall Street investment, will advance investor relations and corporate communications. President Paul Ramsay emphasized that Rinderman's seasoned background will enhance the company's outreach at this pivotal time, coinciding with regulatory advancements and successful pre-clinical trials. CanaQuest, focused on cannabinoid-based health products, is preparing for an e-commerce launch and has received international award recognition.

Positive

• Experienced leadership addition with Rob Rinderman as Director of Communications.
• Progress towards regulatory pathways and completed pre-clinical trials.
• Strong academic partnership with Dr. Laviolette and recognized international awards.
• Upcoming direct-to-consumer e-commerce launch and strategic alliances in place.

Negative

• None.

TORONTO, ON / ACCESSWIRE / April 7, 2021 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of Communications. Mr. Rinderman will focus on managing a proactive investor relations and corporate communications program, further expanding investor community and media awareness about the company's material corporate developments and future prospects.

"We are delighted that a seasoned communications professional with decades of financial experience has agreed to join our team at this important time in our corporate evolution," stated CanaQuest President Paul Ramsay. "We believe adding a veteran like Rob to help us present our story to a wider and receptive audience is a key asset for us moving forward."

Mr. Rinderman brings 35+ years of Wall Street investment industry experience to CanaQuest. After beginning his career in the early 1980s on the American Stock Exchange as a trader and arbitrageur he pivoted his career in the first half of the 1990s to spearheading proactive investor relations programs on behalf of dozens of public companies across multiple sectors and cap sizes, including multibillion-dollar valuations. Mr. Rinderman has guided companies through the IPO process, follow-on capital raises, acquisitions, and crisis communications. He has also worked as a licensed investment banker, passed the CFA Level One, and has an MBA from NYU Stern School.

Rob Rinderman added, "I am very excited to join the CanaQuest senior team at this critical corporate inflection point, reflecting a strong foundation built over recent years. Multiple positive developments are converging including demonstrable progress toward a regulatory pathway, completed pre-clinical trials, plus a strong academic research partnership with Dr. Laviolette (Western University), who recently had a peer-reviewed article published in the European Journal of Neuroscience. CanaQuest has strategic alliances in place for product production, distribution and industry education, an imminent direct-to-consumer (D2C) e-commerce launch, IP asset filings, recent BUY-rated investor research coverage, and the Company also recently received international CBD - R&D award recognition."

For more information on Rob Rinderman - https://www.linkedin.com/in/robrinderman/

CanaQuest Medical Corp is an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical grade botanical compounds. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx, and Mentabinol®Rx, in Canada and the USA. The Company will soon be selling both products through ADC BioMedical Corp, its wholly-owned subsidiary, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. CanaQuest is partnered with a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies addressing anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder (PTSD).

CANAQUEST CONTACT:

Rob Rinderman, Director of Communications
CanaQuest Medical Corp
rob@canaquest.com
Tel: 973.525.6285

SOURCE: CanaQuest Medical Corp.

View source version on accesswire.com:
https://www.accesswire.com/639239/CanaQuest-Medical-Corp-Appoints-Investor-Relations-and-PR-Veteran-Rob-Rinderman-as-its-New-Director-of-Communications

FAQ

What is the significance of Rob Rinderman's appointment at CanaQuest Medical Corp?

Rob Rinderman's appointment is significant as it brings over three decades of experience in investment and communication, aimed at enhancing CanaQuest's investor relations and corporate outreach during a crucial phase of company development.

How does Rob Rinderman's experience benefit CanaQuest Medical Corp?

Rinderman's extensive experience in investor relations, crisis communications, and financial markets is expected to bolster CanaQuest's communication strategy, improving investor engagement and awareness.

What recent developments are highlighted in the CanaQuest Medical Corp press release?

Recent developments include progress towards regulatory pathways, completed pre-clinical trials, and the establishment of an e-commerce platform, alongside recognition from international awards in CBD research.

What products is CanaQuest Medical Corp preparing to launch?

CanaQuest is preparing to launch its cannabinoid health products, Mentanine®Rx and Mentabinol®Rx, through its subsidiary ADC BioMedical Corp after obtaining the necessary licenses.